SOURCE: International Stem Cell Corporation

International Stem Cell Corporation

November 13, 2012 08:30 ET

International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Latest Product Launch

CARLSBAD, CA--(Marketwire - Nov 13, 2012) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company, today announced the commercial launch of its newest stem cell based skin care product by wholly-owned subsidiary Lifeline Skin Care, Inc.

The new Lifeline® Eye Firming Complex is now available to shareholders, followers and supporters of ISCO and Lifeline Skin Care. The product will be available online (www.lifelineskincare.com), in selected spas and medical clinics on November 15, 2012.

Lifeline Eye Firming Complex complements the current anti-aging product line introduced in November 2010 and available in selected luxury spas, medical offices and online. The new, extended Lifeline product line will be promoted by recently engaged celebrities including Emme, the supermodel and author who was twice-named one of People magazine's 50 Most Beautiful People, and Glamour magazine's Woman of the Year; and Jennifer Galardi, a celebrity trainer, nationally recognized fitness and yoga guru, and the face for fitness brands Adidas, Under Armour, New Balance and Nike.

According to supermodel and beauty expert Emme, "Women are concerned about their appearance, and they're especially concerned about the lines and wrinkles around their eyes. That's why they'll like Lifeline's new eye cream -- women want something that really works."

Eye creams are considered a "must-have" in anti-aging skincare, and are typically the most popular product with customers. The new Eye Firming Complex includes novel ingredients designed to produce beneficial results, including peptides and HSC-X™ -- the human stem cell extract developed and patented by International Stem Cell Corporation which is used in the Company's anti-aging Day and Night serums.

"This addition to our skincare line has been highly anticipated," says Donna Queen, President of Lifeline Skin Care. "An eye treatment was the #1 request by our customers."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, potential sales growth, expectations regarding new distribution channels and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contact Information

  • Contacts:
    International Stem Cell Corporation
    Dr. Simon Craw
    Executive Vice President
    Phone: 760-940-6383
    Email: Email Contact

    Investor Relations:
    MZ Group
    Mark McPartland
    Senior Vice President
    Phone: 212-301-7130
    Email: Email Contact
    Web: www.mzgroup.com